BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24727322)

  • 41. PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.
    Lin F; de Gooijer MC; Hanekamp D; Chandrasekaran G; Buil LC; Thota N; Sparidans RW; Beijnen JH; Würdinger T; van Tellingen O
    Clin Cancer Res; 2017 Mar; 23(5):1286-1298. PubMed ID: 27553832
    [No Abstract]   [Full Text] [Related]  

  • 42. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice.
    Spiro AS; Wong A; Boucher AA; Arnold JC
    PLoS One; 2012; 7(4):e35937. PubMed ID: 22536451
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice.
    Loos NHC; Martins MLF; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Int J Pharm; 2024 Jan; 650():123708. PubMed ID: 38135258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.
    de Gooijer MC; Zhang P; Weijer R; Buil LCM; Beijnen JH; van Tellingen O
    Int J Cancer; 2018 Jan; 142(2):381-391. PubMed ID: 28921565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.
    Shukla S; Zaher H; Hartz A; Bauer B; Ware JA; Ambudkar SV
    Pharm Res; 2009 Feb; 26(2):480-7. PubMed ID: 18841445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.
    Zhang P; de Gooijer MC; Buil LC; Beijnen JH; Li G; van Tellingen O
    Int J Cancer; 2015 Oct; 137(8):2007-18. PubMed ID: 25868794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.
    de Gooijer MC; Zhang P; Thota N; Mayayo-Peralta I; Buil LC; Beijnen JH; van Tellingen O
    Invest New Drugs; 2015 Oct; 33(5):1012-9. PubMed ID: 26123925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abcb1a and Abcb1b expression in senescence-accelerated mouse (SAM).
    Wu B; Ueno M; Kusaka T; Onodera M; Huang CL; Hosomi N; Kanenishi K; Sakamoto H
    Neurosci Lett; 2009 May; 456(1):34-8. PubMed ID: 19429129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice.
    Li J; Yue M; Zhou D; Wang M; Zhang H
    Food Chem Toxicol; 2017 Sep; 107(Pt A):68-73. PubMed ID: 28587984
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.
    Schoeppler KE; Aquilante CL; Kiser TH; Fish DN; Zamora MR
    Clin Transplant; 2014 May; 28(5):590-7. PubMed ID: 24628014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone.
    Jin M; Shimada T; Yokogawa K; Nomura M; Kato Y; Tsuji A; Miyamoto K
    Int J Pharm; 2006 Feb; 309(1-2):81-6. PubMed ID: 16384676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol.
    Zander SA; Kersbergen A; Sol W; Gonggrijp M; van de Wetering K; Jonkers J; Borst P; Rottenberg S
    Cancer Prev Res (Phila); 2012 Aug; 5(8):1053-60. PubMed ID: 22767648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.
    Robillard KR; Chan GN; Zhang G; la Porte C; Cameron W; Bendayan R
    Antimicrob Agents Chemother; 2014; 58(3):1713-22. PubMed ID: 24379203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
    Lin F; de Gooijer MC; Roig EM; Buil LC; Christner SM; Beumer JH; Würdinger T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2014 May; 20(10):2703-13. PubMed ID: 24647572
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Irinotecan pathway genotype analysis to predict pharmacokinetics.
    Mathijssen RH; Marsh S; Karlsson MO; Xie R; Baker SD; Verweij J; Sparreboom A; McLeod HL
    Clin Cancer Res; 2003 Aug; 9(9):3246-53. PubMed ID: 12960109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.
    Seamon JA; Rugg CA; Emanuel S; Calcagno AM; Ambudkar SV; Middleton SA; Butler J; Borowski V; Greenberger LM
    Mol Cancer Ther; 2006 Oct; 5(10):2459-67. PubMed ID: 17041089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.